替吉奥联合化疗治疗中晚期非小细胞肺癌的疗效和安全性的Meta分析

目的:系统评价替吉奥联合化疗对比单纯化疗治疗中晚期非小细胞肺癌的疗效和安全性。方法:计算机检索中国期刊全文数据库、维普全文数据库、万方数据库、PubMed、Medline、EMBase中关于替吉奥联合化疗对比单纯化疗治疗中晚期非小细胞肺癌的随机对照试验(RCT),对纳入的RCT采用Cochorane系统评价的方法进行评价,采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入5项研究,合计884例患者。Meta分析结果显示,试验组患者近期疗效有效率OR=1.02,95%CI(0.57,1.82),P=0.96)]、1年生存率OR=1.62,95%CI(0.70,3.76),P=0.26]与对照组比较差异无统计学意义;试验组患者的白细胞减少发生率OR=0.23,95%CI(0.16,0.32),P<0.000]、胃肠道反应发生率OR=0.35,95%CI(0.14,0.88),P=0.03]显著低于对照组,两组比较差异有统计学意义。结论:替吉奥联合化疗治疗中晚期非小细胞肺癌有一定的临床疗效,并能显著降低患者不良反应发生率,提高患者生存质量,但该结论仍需要多中心、大样本的RCT进一步验证。

A Meta-analysis of Efficacy and Safety of S-1 Combined with Chemotherapy on Moderate and Advanced Non-small Cell Lung Cancer

OBJECTIVE： To evaluate the efficacy and safety of S-1 combined with chemotherapy on moderate and advanced non-small cell lung cancer. METHODS： Retrieved from CNKI, VIP, Wanfang database, PubMed, Medline and EMBase, RCTs about S-1 alone or combined with chemotherapy for moderate and advanced lung cancer were collected and evaluated by Cochorane systematic review. Meta-Analysis was carried out by using Rev Man 5.2 software. RESULTS： 5 studies were included, involving 884 patients. Meta-analysis showed that there were no statistical significance in short-term efficacy OR= 1.02,95% CI（0.57, 1.82）, P=0.96）] and 1-year survival rate OR= 1.62,95%CI（0.70,3.76） ,P=0.26] of trial group, compared with control group; the incidence of aleukocytosis OR=0.23, 95%CI（0.16,0.32）, P〈0.000] and gastrointestinal reaction OR=0.35, 95% CI（0.14,0.88）, P=0.03] in trial group were significantly lower than control group; there was statistical significance. CONCLUSIONS： S-1 combined with chemotherapy is effective in the treatment of moderate and advanced non-small cell lung cancer, reduce the incidence of ADR and improve the quality of life. However, multi-center large-scale RCTs are required for further validation.